Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens.

Hall CE, Hagan LM, Bergmann-Leitner E, Tosh DM, Bennett JW, Regules JA, Chuang I, Angov E, Dutta S, Chattopadhyay D, Yadava A.

Infect Immun. 2019 Feb 21;87(3). pii: e00541-18. doi: 10.1128/IAI.00541-18. Print 2019 Mar.

2.

Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.

França CT, White MT, He WQ, Hostetler JB, Brewster J, Frato G, Malhotra I, Gruszczyk J, Huon C, Lin E, Kiniboro B, Yadava A, Siba P, Galinski MR, Healer J, Chitnis C, Cowman AF, Takashima E, Tsuboi T, Tham WH, Fairhurst RM, Rayner JC, King CL, Mueller I.

Elife. 2017 Sep 26;6. pii: e28673. doi: 10.7554/eLife.28673.

3.

Recent Wetting and Glacier Expansion in the Northwest Himalaya and Karakoram.

Yadav RR, Gupta AK, Kotlia BS, Singh V, Misra KG, Yadava AK, Singh AK.

Sci Rep. 2017 Jul 21;7(1):6139. doi: 10.1038/s41598-017-06388-5.

4.

Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.

Longley RJ, França CT, White MT, Kumpitak C, Sa-Angchai P, Gruszczyk J, Hostetler JB, Yadava A, King CL, Fairhurst RM, Rayner JC, Tham WH, Nguitragool W, Sattabongkot J, Mueller I.

Malar J. 2017 Apr 28;16(1):178. doi: 10.1186/s12936-017-1826-8.

5.

Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax.

Yadava A, Waters NC.

PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005164. doi: 10.1371/journal.pntd.0005164. eCollection 2017 Jan. No abstract available.

7.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, Cohen J, Ballou WR, Polhemus ME, Vanloubbeeck YF, Vekemans J, Ockenhouse CF.

PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423. eCollection 2016 Feb.

8.

Particle-based platforms for malaria vaccines.

Wu Y, Narum DL, Fleury S, Jennings G, Yadava A.

Vaccine. 2015 Dec 22;33(52):7518-24. doi: 10.1016/j.vaccine.2015.09.097. Epub 2015 Oct 11. Review.

9.

Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region.

Yadava A, Hall CE, Sullivan JS, Nace D, Williams T, Collins WE, Ockenhouse CF, Barnwell JW.

PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3268. doi: 10.1371/journal.pntd.0003268. eCollection 2014 Oct.

10.

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.

Vanloubbeeck Y, Pichyangkul S, Bayat B, Yongvanitchit K, Bennett JW, Sattabongkot J, Schaecher K, Ockenhouse CF, Cohen J, Yadava A; P. vivax vaccine study group.

Vaccine. 2013 Dec 16;31(52):6216-24. doi: 10.1016/j.vaccine.2013.10.041. Epub 2013 Oct 19.

PMID:
24144477
11.

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.

Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF.

N Engl J Med. 2013 Oct 3;369(14):1381-2. doi: 10.1056/NEJMc1301936. No abstract available.

12.

Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy.

Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F.

Infect Immun. 2013 Aug;81(8):2882-7. doi: 10.1128/IAI.00461-13. Epub 2013 May 28.

13.

Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.

Yadava A, Nurmukhambetova S, Pichugin AV, Lumsden JM.

J Infect Dis. 2012 May 1;205(9):1456-63. doi: 10.1093/infdis/jis220. Epub 2012 Mar 29.

PMID:
22457289
14.

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A.

Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13.

PMID:
22425788
15.

Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine.

Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ.

PLoS One. 2012;7(2):e31472. doi: 10.1371/journal.pone.0031472. Epub 2012 Feb 6.

16.

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction.

Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ.

Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1080-5. doi: 10.1073/pnas.1112648109. Epub 2012 Jan 12.

17.

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A.

Infect Immun. 2011 Sep;79(9):3492-500. doi: 10.1128/IAI.05257-11. Epub 2011 Jun 20.

18.

Margin of error in alignment: a study undertaken when converting from conventional to computer-assisted total knee arthroplasty.

Maniar RN, Johorey AC, Pujary CT, Yadava AN.

J Arthroplasty. 2011 Jan;26(1):82-7. doi: 10.1016/j.arth.2009.11.023. Epub 2010 Feb 19.

PMID:
20171044
19.

Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa.

Culleton R, Ndounga M, Zeyrek FY, Coban C, Casimiro PN, Takeo S, Tsuboi T, Yadava A, Carter R, Tanabe K.

J Infect Dis. 2009 Nov 1;200(9):1465-9. doi: 10.1086/644510.

PMID:
19803728
20.

Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.

Bell BA, Wood JF, Bansal R, Ragab H, Cargo J 3rd, Washington MA, Wood CL, Ware LA, Ockenhouse CF, Yadava A.

Vaccine. 2009 Feb 25;27(9):1448-53. doi: 10.1016/j.vaccine.2008.12.027. Epub 2009 Jan 10.

PMID:
19138714
21.

Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis.

Hartzell JD, Aronson NE, Weina PJ, Howard RS, Yadava A, Wortmann GW.

Am J Trop Med Hyg. 2008 Dec;79(6):843-6.

PMID:
19052290
22.

A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF.

Infect Immun. 2007 Mar;75(3):1177-85. Epub 2006 Dec 11.

23.

Protein disulfide isomerase assisted protein folding in malaria parasites.

Mahajan B, Noiva R, Yadava A, Zheng H, Majam V, Mohan KV, Moch JK, Haynes JD, Nakhasi H, Kumar S.

Int J Parasitol. 2006 Aug;36(9):1037-48. Epub 2006 May 30.

PMID:
16806221
24.
26.
27.

Trafficking of Plasmodium chabaudi adami-infected erythrocytes within the mouse spleen.

Yadava A, Kumar S, Dvorak JA, Milon G, Miller LH.

Proc Natl Acad Sci U S A. 1996 May 14;93(10):4595-9.

28.

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC.

Mol Med. 1995 Mar;1(3):325-32.

30.

T-cell responses to fractionated antigens of Mycobacterium w, a candidate anti-leprosy vaccine, in leprosy patients.

Yadava A, Suresh NR, Zaheer SA, Talwar GP, Mukherjee R.

Scand J Immunol. 1991 Jul;34(1):23-31.

PMID:
2068531

Supplemental Content

Loading ...
Support Center